Advertisement

CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Standard Approach for Inactive, Early CLL Remains a Wait-and-Watch Strategy

June 12th 2023

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

Study Examines Calquence in Older CLL Population

June 9th 2023

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

Cancer Causes Me to Live Life With Uncertainty

June 1st 2023

Days before I went on vacation, I learned that my blood cancer might have progressed to a more aggressive disease.

Vacationing With a New Cancer Companion

May 15th 2023

Before leaving on vacation, I had to make sure I had enough of my cancer medication to last me through the trip.

Imbruvica May Cause High Blood Pressure, Expert Says Patients ‘Shouldn’t Be Afraid’

May 4th 2023

Findings from a study demonstrated that patients may develop hypertension, or high blood pressure, as a result of treatment with Imbruvica for CLL, although it may be quickly managed without drug-drug interactions.

My Cancer Scare Story Continued

April 21st 2023

An ultrasound revealed a solid mass in my breast that would need further follow-up.

Novel CAR-T Cell Therapy to Be Studied in Blood, Breast Cancers

April 4th 2023

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.

FDA Approvals From Winter 2023 You May Have Missed

March 21st 2023

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Developmental Pathways: A Key to Effective Treatments for Lymphoid Malignancies

March 18th 2023

Personalized medicine means not only more powerful drugs for cancers, but also more precise mechanisms that target the specific consequence of mutations and other alterations that drive cancer cell growth, sparing normal cells.

BTK Inhibitors Offer a Revolutionary Treatment of Relapsed CLL/SLL

March 14th 2023

Bruton tyrosine kinase inhibitors have changed the space for treating patients with CLL or SLL, with more on the way to potentially address drug resistance.

I Use My Cancer Diagnosis to Help Others

March 13th 2023

When I share my story and use my cancer diagnosis to help others, cancer becomes a “club” that’s a little more inviting.

Laughing in Silence and Stillness During Cancer

March 2nd 2023

Laughter helped me get through many of cancer’s uncomfortable situations, including a recent MRI, where I was laughing despite not being able to move.

CAR-T Cell Therapy May Confer Responses in Relapsed/Refractory CLL or SLL, Preliminary Data Shows

February 1st 2023

The TRANSCNED CLL 004 trial met its primary endpoint of complete responses with the CAR-T cell therapy Breyanzi in patients with relapsed or refractory CLL or SLL.

Brukinsa Offers Better Response and Less Toxicity for CLL and SLL Treatment, But a Cure Is Still Needed

January 30th 2023

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

FDA Approves Brukinsa for Two Leukemia Types

January 19th 2023

The Food and Drug Administration approved Brukinsa for patients with chronic lymphocytic leukemia or small lymphocytic leukemia.

At the Start of 2023, I’m Reflecting on My New Normal With Cancer

January 11th 2023

Life looks a bit different after my cancer diagnosis and the COVID-19 pandemic, making me even more grateful for the people in my life.

Living Life Between Cancer Appointments

December 26th 2022

When cancer entered our life, fear was a constant. However, we tried to live as joyously as possible between check-ups.

Survival and Treatment Response May Be Further Improved With Brukinsa Versus Imbruvica for CLL/SLL

December 14th 2022

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Calquence Tends to Be a Shorter-Lived Frontline Regimen Than Imbruvica for Leukemia Subtype

December 13th 2022

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

Switching to Subcutaneous Medication for My Cancer-Induced Compromised Immune System Was Life Changing

December 9th 2022

Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system.

When It Comes to Cancer, Are We What We Eat?

November 16th 2022

After being diagnosed with cancer 13 years ago, I began to wonder if my diet had anything to do with it — so I made some changes to eat better.

Can Baking Bread Be Cancer Therapy?

November 1st 2022

I made a point to continue baking a weekly challah bread after I was diagnosed with blood cancer, and it proved to be therapeutic.

My Oncologist Gave Me Hope

October 22nd 2022

After being diagnosed with lymphoma, I scheduled consultations with three oncologists, but only one provided me with the hope I needed.

First Patient Receives Investigational CAR-T Cell Therapy in Trial Assessing the Treatment for Lymphoma, Leukemia

October 14th 2022

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

Blood Cancer Drug, Copiktra, May Increase Risk of Death, Severe Side Effects, FDA Warns

July 5th 2022

Long-term clinical trial data showed that the use of Copiktra was associated with an increased rate of death and severe side effects for patients with chronic lymphocytic leukemia and small cell leukemia.

Time-Limited Venclexta Regimens Outperform Chemoimmunotherapy in CLL

June 13th 2022

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

June 5th 2022

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Better Data Needed to Approve Future PI3K Inhibitors for Blood Cancers, FDA Panel Recommends

April 25th 2022

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

Certain Blood Cancer Treatments Pulled from US Market After Treatment Results Fail to Show Improved Survival

April 21st 2022

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

FDA Places Partial Hold on Trial Investigating Novel Drug in Patients With Leukemia and Lymphoma

April 12th 2022

The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.

NEXT PAGE
PREVIOUS PAGE
Advertisement
Advertisement